blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2401256

EP2401256 - Compounds as bradykinin B1 antagonists [Right-click to bookmark this link]
Former [2012/01]COMPOUNDS AS BRADYKININ B1 ANTAGONISTS
[2012/36]
StatusNo opposition filed within time limit
Status updated on  21.02.2014
Database last updated on 28.09.2024
Most recent event   Tooltip29.04.2016Lapse of the patent in a contracting statepublished on 01.06.2016  [2016/22]
Applicant(s)For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[N/P]
Former [2012/01]For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
Inventor(s)01 / HAUEL, Norbert
Boehringer Ingelheim GmbH
CD Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
02 / CECI, Angelo
Boehringer Ingelheim GmbH
CD Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
03 / DOODS, Henri
Boehringer Ingelheim GmbH
CD Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
04 / KONETZKI, Ingo
Boehringer Ingelheim GmbH
CD Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
05 / MACK, Juergen
Boehringer Ingelheim GmbH
CD Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
06 / PRIEPKE, Henning
Boehringer Ingelheim GmbH
CD Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
07 / SCHULER-METZ, Annette
Boehringer Ingelheim GmbH
CD Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
08 / WALTER, Rainer
Boehringer Ingelheim GmbH
CD Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
09 / WIEDENMAYER, Dieter
Boehringer Ingelheim GmbH
CD Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
 [2012/01]
Representative(s)Simon, Elke Anna Maria, et al
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2012/40]
Former [2012/01]Hammann, Heinz
Boehringer Ingelheim Pharma GmbH & Co. KG Binger Strasse 173
55216 Ingelheim am Rhein / DE
Application number, filing date10711628.723.02.2010
WO2010EP52232
Priority number, dateEP2009015377826.02.2009         Original published format: EP 09153778
[2012/01]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report
No.:WO2010097372
Date:02.09.2010
Language:DE
[2010/35]
Type: A1 Application with search report 
No.:EP2401256
Date:04.01.2012
Language:DE
The application published by WIPO in one of the EPO official languages on 02.09.2010 takes the place of the publication of the European patent application.
[2012/01]
Type: B1 Patent specification 
No.:EP2401256
Date:17.04.2013
Language:DE
[2013/16]
Search report(s)International search report - published on:EP02.09.2010
ClassificationIPC:C07D211/62, C07D213/81, C07D233/90, C07D239/28, C07D261/18, C07D271/10, C07D239/557, C07D207/277, C07D237/24, A61K31/165, A61K31/44, A61K31/505, A61K31/506, C07D401/12, C07D405/12
[2012/01]
CPC:
C07D405/12 (EP,US); C07D239/28 (EP,KR,US); A61P1/00 (EP);
A61P11/06 (EP); A61P11/08 (EP); A61P11/14 (EP);
A61P13/00 (EP); A61P13/08 (EP); A61P13/10 (EP);
A61P17/00 (EP); A61P17/02 (EP); A61P17/04 (EP);
A61P17/06 (EP); A61P19/02 (EP); A61P19/10 (EP);
A61P21/00 (EP); A61P25/00 (EP); A61P25/02 (EP);
A61P25/04 (EP); A61P25/06 (EP); A61P25/08 (EP);
A61P25/16 (EP); A61P25/24 (EP); A61P25/28 (EP);
A61P29/00 (EP); A61P3/04 (EP); A61P3/10 (EP);
A61P31/04 (EP); A61P35/00 (EP); A61P37/02 (EP);
A61P37/08 (EP); A61P43/00 (EP); A61P9/00 (EP);
A61P9/10 (EP); A61P9/12 (EP); C07C237/24 (EP,US);
C07D207/277 (EP,US); C07D211/62 (EP,US); C07D213/81 (EP,US);
C07D233/90 (EP,US); C07D239/557 (EP,KR,US); C07D261/18 (EP,US);
C07D271/10 (EP,US); C07D401/12 (EP,US); C07C2601/02 (EP,KR,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/01]
Extension statesBA26.09.2011
RS26.09.2011
TitleGerman:Verbindungen als Bradykinin-B1-Antagonisten[2012/36]
English:Compounds as bradykinin B1 antagonists[2012/36]
French:Composés comme antagonistes de la bradykinine B1[2012/36]
Former [2012/01]VERBINDUNGEN ALS BRADYKININ-B1-ANTAGONISTEN
Former [2012/01]COMPOUNDS AS BRADYKININ B1 ANTAGONISTS
Former [2012/01]COMPOSÉS UTILISÉS COMME ANTAGONISTES DE LA BRADYKININE B1
Entry into regional phase26.09.2011National basic fee paid 
26.09.2011Designation fee(s) paid 
26.09.2011Examination fee paid 
Examination procedure26.09.2011Examination requested  [2012/01]
06.09.2012Communication of intention to grant the patent
12.12.2012Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
25.01.2013Communication of intention to grant the patent
20.02.2013Fee for grant paid
20.02.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  06.09.2012
Opposition(s)20.01.2014No opposition filed within time limit [2014/13]
Fees paidRenewal fee
29.02.2012Renewal fee patent year 03
27.02.2013Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipSM17.04.2013
[2016/22]
Cited inInternational search[A]WO03066577  (MERCK & CO INC [US], et al) [A] 1,29-34 * claims 1,36-40; tables 1-10 *;
 [A]WO2004019868  (MERCK & CO INC [US], et al) [A] 1,29-34 * claims 1,27-29; tables 1-6 *;
 [A]WO2005016886  (MERCK & CO INC [US], et al) [A] 1,29-34* examples 1-24; claims 1-13 *;
 [A]WO2005085198  (MERCK & CO INC [US], et al) [A] 1,29-34 * claims 1-10; table 1 *
by applicantWO2006120176
    - Houben-Weyl, Methoden der Organischen Chemie, vol. 15/2
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.